1. Clinical & Scientific Overview
Hyaluronic Acid / Sodium Hyaluronate (TIP-MED-000606, Reference Code [COS-02]) is classified under
Cosmetics & Cosmeceutical Ingredients (Cosmetics Rules, 2020) as a Cosmetic Science & Dermopharmaceutics • Humectant & Epidermal Hydration Polymer.
Within the Indian regulatory and compendial framework, it is governed under Cosmetic humectant under Cosmetics Rules, 2020; distinct from injectable cross-linked dermal fillers (which are regulated as Class C/D Medical Devices under MDR 2017)..
INCI Standard: Sodium Hyaluronate / Hyaluronic Acid (IS 4707 / Cosmetics Rules, 2020 Compliant)
0.1% to 2.0% in aqueous serums, gels, and emulsions; pH 5.0–7.5
Dermopharmaceutics, INCI Formulation & Cosmetics Rules 2020 Compliance
Sodium Hyaluronate / Hyaluronic AcidHumectant & Epidermal Hydration Polymer
0.1% to 2.0% in aqueous serums, gels, and emulsions; pH 5.0–7.5
Irritation, Sensitisation & Photoprotection Considerations: Ultra-low-molecular-weight fragments (<20–50 kDa) can penetrate compromised barriers and trigger pro-inflammatory TLR2/TLR4 signalling in rosacea/eczema-prone skin; in arid climates (<30% humidity), apply to damp skin and seal with an occlusive moisturiser.
Chemical Stability & Formulation Incompatibilities: Incompatible with cationic surfactants and quaternary ammonium compounds (polyquaterniums, benzalkonium chloride), which precipitate anionic hyaluronate chains.
Statutory Cosmetic vs Drug Distinction (Cosmetics Rules, 2020 & BIS IS 4707): Cosmetic humectant under Cosmetics Rules, 2020; distinct from injectable cross-linked dermal fillers (which are regulated as Class C/D Medical Devices under MDR 2017).
3. Mechanism of Action & Pharmacodynamics
Linear glycosaminoglycan composed of repeating D-glucuronic acid and N-acetyl-D-glucosamine disaccharide units that binds up to 1,000 times its weight in water via hydrogen bonding; High-Molecular-Weight (HMW >1,000 kDa) forms a breathable surface film reducing transepidermal water loss (TEWL), while Low-Molecular-Weight (LMW 50–300 kDa) hydrates superficial stratum corneum layers.
4. Therapeutic Indications & Evidence-Supported Uses
- Surface humectant hydration for dehydrated skin
- Cosmetic smoothing of superficial dehydration lines
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Cosmetic Formulation Concentration & pH Window: 0.1% to 2.0% in aqueous serums, gels, and emulsions; pH 5.0–7.5
Administration & Meal Timing: External topical use only (0.1% to 2.0% in aqueous serums, gels, and emulsions; pH 5.0–7.5). Incompatible with cationic surfactants and quaternary ammonium compounds (polyquaterniums, benzalkonium chloride), which precipitate anionic hyaluronate chains.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Stratum corneum partitioning and epidermal retention governed by molecular weight (<500 Da rule), logP, and formulation pH; cosmetic ingredients are formulated for local epidermal/corneocyte conditioning without systemic pharmacological action.
Local epidermal enzymatic hydrolysis or oxidation where applicable (e.g., esterases for retinyl/tocopheryl esters).
Not applicable (topical cosmetic ingredient with negligible systemic exposure when used on intact skin).
Not applicable (topical external cosmetic use).
7. Contraindications, Precautions & High-Risk Warnings
- Known allergic contact dermatitis or hypersensitivity to Sodium Hyaluronate / Hyaluronic Acid
- Application to open wounds, abraded skin, or acute infectious dermatoses
- Ultra-low-molecular-weight fragments (<20–50 kDa) can penetrate compromised barriers and trigger pro-inflammatory TLR2/TLR4 signalling in rosacea/eczema-prone skin; in arid climates (<30% humidity), apply to damp skin and seal with an occlusive moisturiser.
Key Clinical Precautions: Ultra-low-molecular-weight fragments (<20–50 kDa) can penetrate compromised barriers and trigger pro-inflammatory TLR2/TLR4 signalling in rosacea/eczema-prone skin; in arid climates (<30% humidity), apply to damp skin and seal with an occlusive moisturiser.
8. Adverse Effects Profile
- Ultra-low-molecular-weight fragments (<20–50 kDa) can penetrate compromised barriers and trigger pro-inflammatory TLR2/TLR4 signalling in rosacea/eczema-prone skin; in arid climates (<30% humidity), apply to damp skin and seal with an occlusive moisturiser.
- Ultra-low-molecular-weight fragments (<20–50 kDa) can penetrate compromised barriers and trigger pro-inflammatory TLR2/TLR4 signalling in rosacea/eczema-prone skin; in arid climates (<30% humidity), apply to damp skin and seal with an occlusive moisturiser.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Incompatible with cationic surfactants and quaternary ammonium compounds (polyquaterniums, benzalkonium chloride), which precipitate anionic hyaluronate chains.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Formulation Stability & Compatibility Check: Incompatible with cationic surfactants and quaternary ammonium compounds (polyquaterniums, benzalkonium chloride), which precipitate anionic hyaluronate chains.
Pharmacist Patient Counselling Points:
- Perform a 24–48 hour forearm patch test before introducing a new active cosmeceutical onto facial skin.
- Apply broad-spectrum SPF 30+ PA+++ sunscreen every morning, especially when using AHAs, BHAs, retinol, or brightening actives.
- Cosmetic products clean, condition, or protect superficial skin appearance; persistent acne, melasma, rosacea, or eczema requires medical dermatology evaluation.
Storage, Stability & Dispensing Safeguards: Incompatible with cationic surfactants and quaternary ammonium compounds (polyquaterniums, benzalkonium chloride), which precipitate anionic hyaluronate chains.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Cosmetics Rules, 2020 (CDSCO, Ministry of Health & Family Welfare, Govt. of India); Bureau of Indian Standards (BIS) IS 4707 (Part 1 & Part 2) Classification of Cosmetic Raw Materials and Adjuncts.
Official Verification Portals: CDSCO — Cosmetics Division & Cosmetics Rules, 2020 • Bureau of Indian Standards (BIS) — IS 4707 Cosmetic Standards
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [COS-19] Piroctone Olamine — Cosmetic Science & Dermopharmaceutics • Hydroxamic Acid Derivativ
- [COS-20] Palmitoyl Pentapeptide-4 (Matrixyl) & Signal Peptides — Cosmetic Science & Dermopharmaceutics • Lipopeptide Matrikine Bio
- [COS-01] Niacinamide (Vitamin B3 Cosmetic Grade) — Cosmetic Science & Dermopharmaceutics • Skin Conditioning Agent,
- [COS-03] Retinol (Cosmetic All-Trans-Retinol) — Cosmetic Science & Dermopharmaceutics • Cosmetic Skin-Conditionin
